

# The simple 10-item PARC tool to predict childhood asthma – an external validation

Pedersen ESL, Spycher BD, de Jong C, Halbeisen F, Ramette A, Gaillard EA, Granell R, Henderson AJ, Kuehni CE

**Corresponding author:** Prof. Claudia E. Kuehni, Institute of Social and Preventive Medicine, University of Bern, Finkenhubelweg 11, 3012 Bern, Switzerland, +41 31 631 35 07, [Claudia.kuehni@ispm.unibe.ch](mailto:Claudia.kuehni@ispm.unibe.ch)

## Affiliations

**Eva S L Pedersen**, M.Sc., Institute of Social and Preventive Medicine, University of Bern, Finkenhubelweg 11, 3012 Bern, Switzerland, [eva.pedersen@ispm.unibe.ch](mailto:eva.pedersen@ispm.unibe.ch)

**Ben D Spycher**, Prof., Institute of Social and Preventive Medicine, University of Bern, Finkenhubelweg 11, 3012 Bern, Switzerland, [ben.spycher@ispm.unibe.ch](mailto:ben.spycher@ispm.unibe.ch)

**Carmen de Jong**, Dr., Institute of Social and Preventive Medicine, University of Bern, Finkenhubelweg 11, 3012 Bern, Switzerland, [carmen.dejong@ispm.unibe.ch](mailto:carmen.dejong@ispm.unibe.ch)

**Florian Halbeisen**, M.Sc., Institute of Social and Preventive Medicine, University of Bern, Finkenhubelweg 11, 3012 Bern, Switzerland, [florian.halbeisen@ispm.unibe.ch](mailto:florian.halbeisen@ispm.unibe.ch)

**Alban Ramette**, PhD, Institute for Infectious Diseases, University of Bern, Friedbühlstrasse 51, 3001 Bern, Switzerland, [alban.ramette@ifik.unibe.ch](mailto:alban.ramette@ifik.unibe.ch)

**Erol A Gaillard**, Dr., University of Leicester, [eag15@leicester.ac.uk](mailto:eag15@leicester.ac.uk)

**Raquel Granell**, PhD, Population Health Sciences, Bristol Medical School, University of Bristol, Oakfield House, Oakfield Grove, Bristol BS8 2BN, UK,

[Raquel.granell@bristol.ac.uk](mailto:Raquel.granell@bristol.ac.uk)

25 **A John Henderson**, Prof., Population Health Sciences, Bristol Medical School,

26 University of Bristol, Oakfield House, Oakfield Grove, Bristol BS8 2BN, UK,

27 [a.j.henderson@bristol.ac.uk](mailto:a.j.henderson@bristol.ac.uk)

28 **Claudia E Kuehni (corresponding author)**, Prof., Institute of Social and Preventive

29 Medicine, University of Bern, Finkenhubelweg 11, 3012 Bern, Switzerland,

30 [Claudia.kuehni@ispm.unibe.ch](mailto:Claudia.kuehni@ispm.unibe.ch)

31

## 32 **Disclosure statement**

33 The authors declare that they have no competing interests.

## 34 **Funding**

35 This study was funded by the Swiss National Science (SNF), grant

36 (32003B\_162820/1). Further funding to develop the SPAC cohort came from the

37 Allergiestiftung U. Müller-Gierok and the Lung league St. Gallen. BD Spycher was

38 supported by an SNF Ambizione fellowship (PZ00P3\_147987).

39 The UK Medical Research Council and Wellcome (Grant ref: 102215/2/13/2) and the

40 University of Bristol provide core support for ALSPAC.

## 41   **Abstract**

### 42   Background

43   External validation of prediction models is important to assess generalisability to  
44   other populations than the one used for model development. The Predicting Asthma  
45   Risk in Children (PARC) tool, developed in the Leicestershire Respiratory Cohort  
46   (LRC), uses information on preschool respiratory symptoms to predict asthma at  
47   school age.

### 48   Objective

49   We performed an external validation of PARC using the Avon Longitudinal Study of  
50   Parents and Children (ALSPAC).

### 51   Methods

52   We defined inclusion criteria, prediction score items at baseline and asthma at  
53   follow-up in ALSPAC to match those used in LRC using information from parent-  
54   reported questionnaires. We assessed performance of PARC by calculating  
55   sensitivity, specificity, predictive values, likelihood ratios, area under the curve  
56   (AUC), Brier score and Nagelkerke's R-squared. Sensitivity analyses varied inclusion  
57   criteria, scoring items and outcomes.

### 58   Results

59   The validation population included 2690 children with preschool respiratory  
60   symptoms of which 373 (14%) had asthma at school age. Discriminative performance  
61   of PARC was similar in ALSPAC (AUC=0.77, Brier score 0.13) as in LRC (0.78, 0.22).  
62   The score cut-off of 4 showed the highest sum of sensitivity (69%) and specificity  
63   (76%) and positive and negative likelihood ratios of 2.87 and 0.41, respectively.

64 Changes to inclusion criteria, scoring items or outcome definitions barely altered the  
65 prediction performance.

66 Conclusion

67 Performing equally well in the validation cohort as in the development cohort, PARC  
68 is a valid tool for predicting asthma in population based cohorts. Its use in clinical  
69 practice is ready to be tested.

70

71 1. What is already known about this topic?

72 Several childhood asthma prediction models have been developed, but few have  
73 been externally validated.

74 2. What does this article add to our knowledge?

75 We found that the simple 10-item PARC asthma prediction tool performed equally  
76 well in a different study population and identified symptomatic preschool children  
77 who were likely to have asthma at school-age.

78 3. How does this study impact current management guidelines?

79 PARC is a simple non-invasive tool for predicting school-age asthma in symptomatic  
80 preschool children. It can be used to recruit high-risk children for clinical trials and its  
81 use in clinical practice is ready to be tested.

82

83

84 **Keywords:**

85 Asthma; Wheeze; Prediction; External Validation; PARC; Leicestershire Respiratory

86 Cohorts; ALSPAC

87    **List of abbreviations**

88    PARC – Predicting Asthma Risk in Children

89    ALSPAC – Avon Longitudinal Study of Parents And Children

90    LRC – Leicestershire Respiratory Cohort study

91    ROC – Receiver Operator Curves

92    AUC – Area Under the Curve

93    PIAMA – Prevalence and Incidence of Asthma and Mite Allergy

94    MAS-90 - Multicentre Allergy Study

95

## 96    **Introduction**

97    Up to 40% of all preschool children have recurrent respiratory symptoms such as  
98    wheeze or cough but only about a quarter of these will have asthma at school age  
99    (1-4). Prediction models can be useful to identify those whose problems will persist.  
100    The ability to make an accurate prognosis can guide clinical decision-making and  
101    facilitate the selection of children for high-risk cohorts or clinical trials (5). Prediction  
102    models must be carefully developed using sound methodology for selecting  
103    prediction variables and examine discriminative performance and assess calibration  
104    (6). Prediction models may however not perform as well when applied to  
105    populations other than the ones they were developed in. External validation (in  
106    another population) is therefore necessary to assess the generalisability (7, 8).  
107  
108    Several models to predict later asthma in preschool children have been developed  
109    (9). Most use a combination of demographic information, symptoms and results of  
110    clinical tests (e.g. lung function or allergic sensitisation) (10-17). These models are  
111    useful for specialised clinical settings, where spirometry, body plethysmography and  
112    skin prick test can be done. Two tools use only demographic information and  
113    symptoms; information easily obtained from parental questionnaires or when taking  
114    patient history in a medical consultation, which makes these models more widely  
115    applicable (18, 19). One of these was developed by our group, the Predicting Asthma  
116    Risk in Children (PARC) tool. It was developed using data from the Leicestershire  
117    Respiratory Cohorts, a population-based cohort study from the United Kingdom (19).  
118    Four childhood asthma prediction models have been externally validated. The  
119    Asthma Predictive Index (API) (10) was validated in five external cohorts (11, 15, 20-

22), the PIAMA risk score (18) was validated in two external cohorts (21, 23), the Isle of Wight was validated in one external cohort (24) and the PARC tool was validated in a German asthma cohort, where it showed good predictive properties (25).

However, this was a cohort, in which mothers with a history of allergy were overrepresented.

We aimed to validate PARC in a larger population based cohort in the Avon Longitudinal Study of Parents and Children (ALSPAC). We calculated measures of prediction performance and assessed the robustness of prediction performance to changes in the inclusion criteria, the prediction score items and the outcome.

## **Methods**

We used the Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD) guidelines to report this external validation study (26).

### **Predicting Asthma Risk in Children (PARC)**

The PARC tool was developed as a simple, low-cost, and non-invasive method to predict the risk of later asthma in symptomatic preschool children (19). It uses parental information about respiratory symptoms in 1-3 year old children to predict parental reported asthma five years later. The 10 scoring factors are: sex, age, wheeze without colds, number of wheezing episodes, shortness of breath due to wheeze, wheeze interfering with daily activities, exercise or allergy as triggers of wheeze, a history of eczema, and parental history of asthma and bronchitis. The published model was developed using the least absolute shrinkage and selection operator (LASSO) penalised logistic regression to avoid overfitting and simplified into

an easy-to-use tool. We validated the tool internally by using the leave-one-out cross-validation method (19). The sample size was judged to be sufficient based on the one-variable-per-ten-events rule, which suggests that at least ten outcome events per potential predictor considered are needed, to develop a model that can generalize to other samples (8). We considered 38 potential binary predictors (from 24 original variables) and the sample included 345 children with asthma.

#### **Development cohort, LCR**

As described previously (19), the PARC tool was developed using data from the Leicestershire Respiratory Cohort study (LRC). The LRC is a longitudinal population-based study from Leicestershire, United Kingdom (27). For the development of PARC, we used data from 6808 children born in 1993-1997. Data for inclusion criteria, prediction score items and outcomes came from questionnaires on respiratory symptoms and general health that parents completed at baseline in 1998 and 1999 when the children were aged 1-3 and at follow-up in 2003 when the children were aged 6-8 years. The Leicestershire Health Authority Research Ethics Committee approved the study.

#### **External validation cohort, ALSPAC**

In the present study, we used data from the ALSPAC cohort to validate the PARC tool. ALSPAC is a longitudinal birth cohort that recruited 14541 pregnant women from Avon, United Kingdom, with expected delivery between April 1991 and December 1992, resulting in 14062 live born children. The study has been described in detail previously (28). Mothers and their partners filled in questionnaires about their own and their child's health approximately yearly from when the children were 6 months old. We used baseline information from the questionnaires filled in when



the child was 1.5, 2.5 and 3.5 years to define inclusion criteria and calculate the prediction score and information from questionnaires completed at age 6 and 7 years to assess asthma at school age. The ALSPAC study was approved by the ALSPAC Ethics and Law Committee and from Local Research Ethics Committees.

#### **Inclusion criteria**

We defined inclusion criteria for ALSPAC that resembled the inclusion criteria used in the LRC (**table 1**). We included children aged 1.5 to 3.5 years from ALSPAC who had had wheeze or cough during the past 12 months (*Has your child experienced wheeze/cough during the past 12 months?*) and saw a doctor for one of these problems (answer category: *yes and saw a doctor*) plus had valid information on current wheeze and use of asthma medication at age 7.5 years.

#### **Calculation of prediction scores**

Items used for the prediction score are presented in **Table 3** for LRC and ALSPAC. In ALSPAC, the same questionnaires were sent to the parents at 1.5, 2.5 and 3.5 years of age. In order to achieve a comparable age distribution in ALSPAC as in the LRC, the baseline information was taken from the questionnaire filled at age 1.5 year for 28% of the study population, at age 2.5 for 57% and at age 3.5 for 15%. The age at which baseline information was taken for a given child, was obtained by random sampling ensuring this overall age distribution. Information on parental history of wheeze, asthma and bronchitis came from a questionnaire sent to the mother at 12 weeks gestation and from a questionnaire sent to the partner when the child was 33 months old. The prediction score was calculated as the sum of score-points from each item (**table 3**). We also assigned predicted probabilities for later asthma to these scores as suggested in our report on the development of PARC (19).

## Definition of outcome

In the original cohort, we had defined the outcome ‘asthma’ as ‘current wheeze plus use of asthma inhalers in the past 12 months’. To match this outcome definition in ALSPAC, we defined ‘asthma’ as ‘yes’ to the parent reported current wheeze (*‘Has he/she had wheeze in the past 12 months’*) plus current use of asthma medication (*‘Please indicate which of the following have been given to your child in the last 12 months? Asthma medication’*).

## Assessing predictive performance

We assessed how well the calculated PARC prediction scores predicted later asthma in children from the ALSPAC cohort using measures of discrimination (the ability of the score to discriminate between children who had asthma at school age and those who had not) and calibration (the ability of the tool to predict the probability of later asthma) (8). To assess discrimination, we calculated sensitivity, specificity, positive predictive value, negative predictive value, and positive and negative likelihood ratios for each possible cut-off value of the score. We also plotted receiver operator curves (ROC) and calculated area under the curve (AUC). To assess calibration, we assigned the probabilities of later asthma to each score value as proposed in the original article by Pescatore et al. (19). Based on these predicted probabilities, we first calculated maximum rescaled Brier score and Nagelkerke’s  $R^2$  as overall performance measures (8). These measures can be interpreted as “goodness-of-fit measures” showing how well the predicted probability approximates the outcome on a scale between 0 and 1, with 1 indicating perfect prediction and 0 representing a non-informative model, in which a constant probability equalling the prevalence of

the outcome is predicted for each child. Details on how to compute these measures are provided in the supplementary text E1. We examined calibration of the PARC tool graphically by plotting the predicted probability for each value of the score against the observed frequency of asthma among ALSPAC children with that score value, using the function `calibrate.plot` and `val.prob.ci.2` from the 'gbm' package in R (29). We excluded children if they had missing information in any of the scoring variables (8%) apart from the item 'partner's history of wheeze, asthma and bronchitis', for which 25% had missing information. For these children, we set missing information about the partner to 'no history'.

In a separate analysis, we recalibrated the PARC scores in the ALSPAC cohort, by fitting a logistic regression of the outcome on the calculated scores (as a linear term) used in the main analysis above. For each child, we then calculated recalibrated scores as the value of the linear predictor from this regression. We then compared calibration performance of these scores with that of the original scores.

We used STATA 14 for data preparation and descriptive analysis and R version 2.1 to study model performance and model fit.

### **Sensitivity analyses**

To test the robustness of PARC, we performed sensitivity analyses in ALSPAC and LRC datasets using alternative definitions of the included population, prediction score items and outcome definitions (**supplementary table E2**). Firstly, we restricted age at baseline by including children aged 1.5 only, 2.5 only and 3.5 years only (only ALSPAC). Secondly, we altered the inclusion criteria to 1) any wheeze in the past 12 months, and 2) any cough in the past 12 months (only in ALSPAC). Thirdly, we

changed items in the prediction score by: 1) excluding 'wheeze triggered by exercise or allergy', as triggers of wheeze were measured differently in ALSPAC (open question) compared with LRC (specific response categories), and 2) exchanging 'wheeze without colds' with 'current wheeze' (only in LRC), 3) setting missing information in the prediction score items to the lowest value instead of excluding children with missing values in the analysis. Fourthly, we used an alternative outcome definitions: severe asthma (ALSPAC: current wheeze and use of asthma medication on at least 3 episodes, LRC: wheeze on at least 4 episodes and use of asthma inhalers).

### **Sample size**

There are no guidelines for the adequate sample size needed for external validations of prediction model but according to a simulation study by Collins et al. (30) ideally 200 events are required. We had more than 300 events (asthma at age 7.5 years) in any of our analyses.

## **Results**

Of the 14,541 children originally recruited in ALSPAC, 7200 children responded to the questionnaires at 1, 2, 3 and 7 years. Of these, 2921 fulfilled the inclusion criteria (saw a doctor for wheeze or cough in the past 12 months) and 2690 were included in our main analysis (231 were excluded due to missing information in one or more prediction score items). Not all questions used to specify inclusion criteria in the LRC were available in ALSPAC resulting in less restrictive inclusion criteria (**table 1**). **Table 2** shows similarities and differences between the two studies including location in the UK and the gender and age distribution. The two cohorts differed considerably in

ethnicity composition (98% whites in ALSPAC, 81% whites and 19% south Asians in LRC).

### **Distribution of PARC score**

For most items of PARC we were able to use similar questions in ALSPAC as in the LRC (**table 3**). There were some differences for 'wheeze without colds', questions on triggers for wheeze and parental history of wheeze and bronchitis. Assigning scores to ALSPAC children resulted in a more left skewed distribution of the PARC score in ALSPAC compared with the LRC (**Figure 1**). The maximum and median values were lower in the ALSPAC cohort (max = 13, median = 2, Interquartile range: 2-4) compared with the LRC cohort (max = 14, median = 4, Interquartile range: 2-6).

### **Frequency of asthma at follow-up**

In ALSPAC, 373 (14%) of the included children had the primary outcome at age 7.5 years compared with 345 (28%) in LRC (**table 2**).

### **Performance of PARC main analysis**

The discriminative ability of PARC was similar in ALSPAC and LRC (**figure 2**). ROC curves from ALSPAC and LRC were almost identical, AUC of 0.77 in ALSPAC and 0.78 in LRC. In ALSPAC, the score cut-off maximizing the sum of sensitivity (69%) and specificity (76%) was 4, in LRC the best cut-off was 5 (sensitivity 72%, specificity 71%). The validation analysis showed positive and negative predictive value of 0.32 and 0.94 and positive and negative likelihood ratios of 2.87 and 0.41, all at score cut-off 4 (discriminative values for all cut-off points in figure 2). Overall performance in

ALSPAC was comparable to that in LRC. The max-scaled Brier score was 0.13 in ALSPAC and 0.22 in LRC, the Nagelkerke's R-squared was 0.23 in ALSPAC and 0.28 in LRC. The calibration assessment showed that PARC scores from the ALSPAC population were associated with a lower frequency of later asthma than predicted from the LRC (**figure 3 and figure 4**). After recalibrating the predicted probabilities in ALSPAC (**figure 4B**), our calibration plot showed good calibration of PARC in ALSPAC (Brier score = 0.17 for recalibrated main model).

### **Sensitivity analyses**

Changes in inclusion criteria, prediction score items and definition of outcome resulted only in minor changes for most performance measures (**table 4**). In sensitivity analyses, PARC performed better in children aged 3.5 years (AUC = 0.78,  $R^2 = 0.26$ ), compared with 1.5 year-olds (AUC = 0.71,  $R^2 = 0.13$ ). Prediction was slightly worse in a population including only children who wheezed (AUC=0.73,  $R^2 = 0.18$ ) compared with those who also saw a doctor or only children who coughed with or without seeing a doctor (AUC = 0.76,  $R^2 = 0.20$ ). The exclusion of trigger variables in ALSPAC barely altered the performance. PARC performed better when the main outcome was severe asthma (AUC = 0.78,  $R^2 = 0.23$ ). Sensitivity analysis where results excluding missing information were compared to results where missing information was set to zero showed no difference in the performance of PARC (data not shown).

### **Discussion**

We found that PARC predicted asthma at school age equally well in the validation cohort, ALSPAC (AUC 0.77), compared with the development cohort, LRC (AUC 0.78). Using a cut-off score value of 4, PARC predicted asthma with a sensitivity of 69% and specificity of 76%, which was similar to what was found in LRC for a cut-off score of 5 (sensitivity = 72% and specificity = 71%). The calibration assessment showed that the observed frequency of asthma was generally lower in ALSPAC than predicted by the PARC score, but when we recalibrated the predicted probabilities to the ALSPAC population, agreement between predicted and observed asthma frequency was good.

### **Limitations and strengths**

The information used to define the included population was not the same in ALSPAC as in LRC. Specifically, the ALSPAC cohort had insufficient information on night cough and cough without colds, so we replaced this information with a general question about cough. These relaxed inclusion criteria has led to inclusion of less severely affected children than the LRC population, which in turn explains the lower prevalence of asthma at school age (14% in ALSPAC compared with 28% in LRC). This did not affect the discriminative ability of PARC, but it affected calibration and the overall performance measures such as the Brier score. Furthermore, we lacked perfectly matched information on items needed to compute the PARC score. Key information for the score such as wheeze without colds and triggers of wheeze were not available in the same detail. However, our sensitivity analysis in ALSPAC suggested that exclusion of triggers of wheeze did not affect the performance much (AUC 0.77, same as main analysis).

335

336 A strength of our study was that we had full access to all data from the development  
337 and the validation cohort, which made it possible to compare the populations and  
338 assess discriminative performance and calibration of PARC directly. Secondly, the  
339 cohort used for the external validation was large and had collected questionnaire  
340 information yearly between birth and the age of 8 years. This enabled us to match  
341 and vary the age at which baseline and outcome information were collected. Thirdly,  
342 less than 5% of the information in the single variables used for scoring (apart from  
343 partner's history of asthma and wheeze) was missing and we therefore excluded  
344 only a small number of the children satisfying the inclusion criteria (8%). Sensitivity  
345 analysis, in which missing information was set to zero, did not change our main  
346 results. Fourthly, for the primary outcome, we had perfectly matching on current  
347 wheeze and use of asthma medication at the age of 7.5 years, and we could  
348 therefore rule out that differences in performance of the PARC tool in ALSPAC and  
349 LRC cohorts were caused by different outcome definitions.

350

### 351 **Comparison with other studies**

352 One other study has investigated the external validity of PARC and found similar  
353 performance compared with the original cohort (25). The study used information  
354 from the German Multicentre Allergy Study (MAS-90) birth cohort with an  
355 overrepresentation of children from allergic parents. The authors included 140  
356 children in their validation population. The authors found that PARC predicted  
357 asthma with AUC= 0.83 and a sensitivity of 0.82, a specificity of 0.69 at a score of 5.



358 The calibration assessment showed good agreement between predicted  
359 probabilities of asthma and observed frequency.

360 Of the other models developed to predict asthma in children, three have been  
361 externally validated (supplementary table E3). The Asthma Predictive Index  
362 developed using the Tucson Children's Respiratory Study in 2000 (10) was externally  
363 validated in five separate studies (11, 15, 20-22), showing generally higher  
364 sensitivity, but lower specificity than in the development cohort, which could partly  
365 be explained by differences in inclusion criteria. Caudri et al. developed an asthma  
366 prediction model using the Prevalence and Incidence of Asthma and Mite Allergy  
367 birth cohort (PIAMA) (18), which was externally validated in a Colombian clinical  
368 cohort of children with wheeze (21) and in the Dutch population-based Generation R  
369 study (23) and showed similar performance compared with the development cohort.

370 The calibration assessment showed that the PIAMA risk score systematically  
371 overestimated asthma risk at age 7 years. Kurukulaaratchy et al. developed a  
372 prediction model in the Isle of Wight birth cohort (13), which was applied in the  
373 British Multicentre Allergy Study (MAS) birth cohort, where calibration showed  
374 different predictive properties compared with the development cohort. The  
375 evidence from these external validation studies and the present study suggests that  
376 these prediction models are generally robust in different populations and  
377 discriminate asthma from no asthma well in different settings, but calibration must  
378 be assessed for the models to accurately predict asthma risk. Among the existing  
379 prediction models that have been externally validated, PARC and the PIAMA risk  
380 score are the models most easily applied in practice as they require no specific  
381 physiological measurements or blood investigations as does for example the API

(supplementary table E3). Additionally, PARC predicts as well or better than other existing asthma prediction tools when comparing the combined sensitivity and specificity using the Youden Index (31) (sensitivity + specificity – 1, calculated based on the maximal sum of sensitivity and specificity), which ranges from 0 to 1 with 1 indicating perfect prediction. Reported values of the Youden index are 0.43 for PARC compared with 0.32 for the API, 0.36 for the PIAMA risk score and 0.38 for the Isle of Wight score (19). PARC has a similar positive likelihood ratio (true positives/false positives) (+LR = 2.5) compared with the PIAMA risk score (+LR = 2.5) but lower than the API (+LR = 7.8) and the Isle of Wight (+LR = 3.4) (supplementary table E3). These differences could be due to different inclusion criteria used for the study populations in which the prediction scores were developed. The API was developed in a general population sample including mostly healthy children. Such a population has a low baseline risk of asthma at follow-up whereas the populations used for PARC and the PIAMA score included only children visiting doctors for wheeze or chronic cough who thus had a higher baseline risk of asthma at follow-up. In a population with low baseline risk, it may be easier to correctly identify those that will not develop asthma, which increases specificity and, assuming the same sensitivity, increases the positive likelihood ratio. Also, the positive likelihood ratio can be interpreted as the ratio of posterior odds (after a model predicts that a child will have asthma based on baseline information) of having later asthma to the prior odds (ignoring baseline information). A higher positive likelihood ratio is needed to achieve the same posterior likelihood of asthma if the baseline risk is low compared to when it is high.

406

407 **Interpretation**

408 PARC predicted asthma better in children who were older at the baseline survey. A  
409 reason for this could be that the aetiology of wheeze in children age less than 2  
410 years is more heterogeneous and only a small proportion will eventually have  
411 asthma. In a study using data from ALSPAC, Henderson et al. (32) investigated  
412 wheezing phenotypes over time and found a majority of children with the  
413 phenotype *transient early wheeze* begin wheezing in the first two years of life. In our  
414 data we saw that more children fulfilled our inclusion criteria early in life (3583 1.5-  
415 year-olds compared to 2238 3.5-year-olds), but the proportion of children that had  
416 asthma at school age was lower among children aged 1.5 years initially (12%) than in  
417 children aged 3.5 years at baseline (19%). This may explain the poorer prediction,  
418 particularly poorer calibration, among 1.5 year-olds.

419 The different phenotypes of wheeze might also explain why the predictive  
420 performance of PARC was better for severe asthma. Several studies have identified a  
421 phenotype characterised by persistence of symptoms from an early age (3, 32, 33).  
422 Children with this phenotype tend to have more wheezing episodes, more often use  
423 bronchodilators, and cough without colds compared with wheeze phenotypes with  
424 late onset transient or viral wheeze. Because severity tends to track (34), PARC  
425 identifies those with more severe disease at school age because these children often  
426 had already severe symptoms early in life. As disease burden is greater in children  
427 with severe asthma, they are the main target group for interventions.

428 The discriminative ability of PARC appears robust to changes in item and population  
429 definitions. Although different questions were used in the two cohorts, they

probably measure similar concepts. This makes PARC useful also in settings with misclassification of information. Outcome prevalence appears to be the more critical factors affecting predictive performance. Therefore, if PARC is to be used in a population with outcome-prevalence very different from that in LRC, we recommend simple recalibration of the PARC, which allows obtaining risk-probabilities that are closer to the observed frequencies. Practically, one approach for calibration could be to examine the prevalence of school-age asthma in the population in question and compare it to LRC or ALSPAC. If the observed frequencies are similar to those in LRC or ALSPAC, the predicted probabilities calculated in the original study or this validation study can be used. If the prevalence is much higher or much lower, it might be necessary to collect (possibly retrospectively from medical records) information from a subsample of children to fill in the PARC tool and thereby calculate new predicted probabilities.

The ALSPAC cohort did not offer the possibility to validate the PARC tool in different ethnic groups as the ALSPAC included 98% whites. The PARC tool would need to be externally validated in a sample with a larger ethnic diversity to determine the generalizability of PARC in different ethnic settings.

The sample size in the original development of the PARC prediction model was estimated to be sufficient according to the one-variable-per-ten-events rule with 24 potential predictor variables (represented by 38 binary variables) and 345 events (35). However, the appropriateness of this rule has been questioned (36). It is possible that our original study did not have sufficient statistical power to identify some important predictors among the 38 predictors considered, although 10 of these were retained in the final model and are used in the PARC tool. That the PARC

tool includes irrelevant predictors as a result of overfitting is less likely as we used penalised logistic regression to build the tool. Furthermore, almost all predictors included in PARC are either recognised risk factors (male sex, parental history) or are indicators of atopy or symptom severity, which are both known to be associated with persistence. The only exception is older age ( $\geq 1$  year), which is a plausible predictor, as wheeze or cough in infancy is more transient and usually associated with respiratory infections.

## **Conclusion**

This validation study showed that PARC has the same ability to identify preschool children who are likely to develop asthma at 7.5 years in a population different from the development cohort. The discriminative ability of the tool appears to be robust to changes in inclusion criteria, scoring variables and outcome definitions suggesting that PARC is robust to misclassification of information. Our study suggests that the tool may need recalibration when applied to populations, in which the outcome prevalence differs greatly from the development cohort. PARC is a valid tool for predicting asthma in pre-school children and its use in clinical practice is ready to be tested.

472

473 **Ethics approval and consent to participate**

474 The ALSPAC study was approved by the ALSPAC Ethics and Law Committee and from  
475 Local Research Ethics Committees. The Leicestershire Health Authority Research  
476 Ethics Committee approved the Leicestershire Respiratory Cohort study.

477

478

479 **Authors' contributions**

480 EP, BS, and CK made substantial contributions to the study conception and design  
481 and were involved in the drafting of the manuscript. AR contributed to the study  
482 management and data preparation. EP, BS and FH were responsible for the statistical  
483 analyses. JH and RG were involved in data collection and preparation of ALSPAC. EP,  
484 BS, FH, CJ, AR, EG, JH, RG and CK critically revised and approved the manuscript.

485

486 **Acknowledgements**

487 We are extremely grateful to all the families who took part in this study, the  
488 midwives for their help in recruiting them, and the whole ALSPAC team, which  
489 includes interviewers, computer and laboratory technicians, clerical workers,  
490 research scientists, volunteers, managers, receptionists and nurses.

491 We are also extremely grateful to all the children and their parents for participating  
492 in the Leicester Respiratory Cohort studies. Data collection was funded by the UK  
493 National Asthma campaign, the University Hospitals of Leicester NHS Trust (R&D),  
494 Leicestershire and Rutland partnership Trust, Medisearch, Trent NHS Regional health  
495 Authority, and the UK Department of Health.

496

497 **Availability of data and material**

498 The LRC dataset is available on reasonable request by contacting Claudia Kuehni. The  
 499 ALSPAC dataset is available by proposals through the ALSPAC Executive Committee  
 500 using the procedures outlined in the ALSPAC Access Policy  
 501 ([www.bristol.ac.uk/alpsac/researchers/access/](http://www.bristol.ac.uk/alpsac/researchers/access/))

502

503 **Figure legends**

504 **Figure 1:** Distribution of the PARC scores\* (relative frequency) in the external  
 505 validation population (ALSPAC, n=2690, black) and original development population  
 506 (LRC, n=1226, grey).

507

508 **Figure 2:** Receiver operating characteristic (ROC) from validation population ALSPAC  
 509 (solid line) and the original development population LRC (dashed line). Numbers (1-  
 510 13) indicate asthma prediction score values and their corresponding positions  
 511 (indicated in red on the figure). The area under the curve (AUC) corresponds to the  
 512 primary outcome in both cohorts. The table above the figure shows sensitivity  
 513 (Sens), specificity (Spec), positive and negative predictive values (PPV, NPV) and  
 514 likelihood ratios (LR+, LR-) for each score point in ALSPAC.

515

516 **Figure 3:** Predicted probability of developing asthma at follow-up in LRC (dashed  
 517 grey line) and probabilities predicted by the recalibrated model in ALSPAC (black  
 518 line).

519


520 **Figure 4:** Calibration assessment of predicted probabilities vs. observed asthma  
521 frequencies in seven equally sized groups. Figure A displays the calibration  
522 assessment for the predicted probabilities calculated in LRC. Figure B displays the  
523 probabilities predicted by the recalibrated model in ALSPAC. Shaded areas represent  
524 exact pointwise 95%-CI for asthma frequency. The diagonal red line represents  
525 perfect calibration.



- 526 1. Brooke AM, Lambert PC, Burton PR, Clarke C, Luyt DK, Simpson H. The  
527 natural history of respiratory symptoms in preschool children. *American journal*  
528 *of respiratory and critical care medicine*. 1995;152(6 Pt 1):1872-8.
- 529 2. Granell R, Henderson AJ, Sterne JA. Associations of wheezing phenotypes  
530 with late asthma outcomes in the Avon Longitudinal Study of Parents and  
531 Children: A population-based birth cohort. *The Journal of allergy and clinical*  
532 *immunology*. 2016.
- 533 3. Martinez FD, Wright AL, Taussig LM, Holberg CJ, Halonen M, Morgan WJ.  
534 Asthma and wheezing in the first six years of life. The Group Health Medical  
535 Associates. *The New England journal of medicine*. 1995;332(3):133-8.
- 536 4. Guilbert TW, Mauger DT, Lemanske RF, Jr. Childhood asthma-predictive  
537 phenotype. *The journal of allergy and clinical immunology In practice*.  
538 2014;2(6):664-70.
- 539 5. Hemingway H, Croft P, Perel P, Hayden JA, Abrams K, Timmis A, et al.  
540 Prognosis research strategy (PROGRESS) 1: a framework for researching clinical  
541 outcomes. *BMJ (Clinical research ed)*. 2013;346:e5595.
- 542 6. Altman DG. Prognostic models: a methodological framework and review  
543 of models for breast cancer. *Cancer investigation*. 2009;27(3):235-43.
- 544 7. Moons KG, Kengne AP, Grobbee DE, Royston P, Vergouwe Y, Altman DG, et  
545 al. Risk prediction models: II. External validation, model updating, and impact  
546 assessment. *Heart (British Cardiac Society)*. 2012;98(9):691-8.
- 547 8. Steyerberg E. *Clinical prediction models: a practical approach to*  
548 *development, validation, and updating*. . Berlin: Springer-Verlag; 2009.
- 549 9. Smit HA, Pinart M, Anto JM, Keil T, Bousquet J, Carlsen KH, et al. Childhood  
550 asthma prediction models: a systematic review. *The Lancet Respiratory*  
551 *medicine*. 2015;3(12):973-84.
- 552 10. Castro-Rodriguez JA, Holberg CJ, Wright AL, Martinez FD. A clinical index  
553 to define risk of asthma in young children with recurrent wheezing. *American*  
554 *journal of respiratory and critical care medicine*. 2000;162(4 Pt 1):1403-6.
- 555 11. Chang TS, Lemanske RF, Jr., Guilbert TW, Gern JE, Coen MH, Evans MD, et  
556 al. Evaluation of the modified asthma predictive index in high-risk preschool  
557 children. *The journal of allergy and clinical immunology In practice*.  
558 2013;1(2):152-6.
- 559 12. Eysink PE, ter Riet G, Aalberse RC, van Aalderen WM, Roos CM, van der  
560 Zee JS, et al. Accuracy of specific IgE in the prediction of asthma: development of  
561 a scoring formula for general practice. *The British journal of general practice :*  
562 *the journal of the Royal College of General Practitioners*. 2005;55(511):125-31.
- 563 13. Kurukulaaratchy RJ, Matthews S, Holgate ST, Arshad SH. Predicting  
564 persistent disease among children who wheeze during early life. *The European*  
565 *respiratory journal*. 2003;22(5):767-71.
- 566 14. Lodrup Carlsen KC, Soderstrom L, Mowinckel P, Haland G, Pettersen M,  
567 Munthe Kaas MC, et al. Asthma prediction in school children; the value of  
568 combined IgE-antibodies and obstructive airways disease severity score. *Allergy*.  
569 2010;65(9):1134-40.
- 570 15. Singer F, Luchsinger I, Inci D, Knauer N, Latzin P, Wildhaber JH, et al.  
571 Exhaled nitric oxide in symptomatic children at preschool age predicts later  
572 asthma. *Allergy*. 2013;68(4):531-8.
- 573 16. van der Mark LB, van Wonderen KE, Mohrs J, van Aalderen WM, ter Riet G,  
574 Bindels PJ. Predicting asthma in preschool children at high risk presenting in


- primary care: development of a clinical asthma prediction score. Primary care  
respiratory journal : journal of the General Practice Airways Group.  
2014;23(1):52-9.
17. Vial Dupuy A, Amat F, Pereira B, Labbe A, Just J. A simple tool to identify  
infants at high risk of mild to severe childhood asthma: the persistent asthma  
predictive score. The Journal of asthma : official journal of the Association for the  
Care of Asthma. 2011;48(10):1015-21.
18. Caudri D, Wijga A, CM AS, Hoekstra M, Postma DS, Koppelman GH, et al.  
Predicting the long-term prognosis of children with symptoms suggestive of  
asthma at preschool age. The Journal of allergy and clinical immunology.  
2009;124(5):903-10.e1-7.
19. Pescatore AM, Dogaru CM, Duembgen L, Silverman M, Gaillard EA,  
Spycher BD, et al. A simple asthma prediction tool for preschool children with  
wheeze or cough. The Journal of allergy and clinical immunology.  
2014;133(1):111-8.e1-13.
20. Leonardi NA, Spycher BD, Strippoli MP, Frey U, Silverman M, Kuehni CE.  
Validation of the Asthma Predictive Index and comparison with simpler clinical  
prediction rules. The Journal of allergy and clinical immunology.  
2011;127(6):1466-72.e6.
21. Rodriguez-Martinez CE, Sossa-Briceno MP, Castro-Rodriguez JA.  
Discriminative properties of two predictive indices for asthma diagnosis in a  
sample of preschoolers with recurrent wheezing. Pediatric pulmonology.  
2011;46(12):1175-81.
22. Amin P, Levin L, Epstein T, Ryan P, LeMasters G, Khurana Hershey G, et al.  
Optimum predictors of childhood asthma: persistent wheeze or the Asthma  
Predictive Index? The journal of allergy and clinical immunology In practice.  
2014;2(6):709-15.
23. Hafkamp-de Groen E, Lingsma HF, Caudri D, Levie D, Wijga A, Koppelman  
GH, et al. Predicting asthma in preschool children with asthma-like symptoms:  
validating and updating the PIAMA risk score. The Journal of allergy and clinical  
immunology. 2013;132(6):1303-10.
24. Matricardi PM, Illi S, Keil T, Wagner P, Wahn U, Lau S. Predicting  
persistence of wheezing: one algorithm does not fit all. The European respiratory  
journal. 2010;35(3):701-3.
25. Grabenhenrich LB, Reich A, Fischer F, Zepp F, Forster J, Schuster A, et al.  
The novel 10-item asthma prediction tool: external validation in the German  
MAS birth cohort. PloS one. 2014;9(12):e115852.
26. Moons KG, Altman DG, Reitsma JB, Collins GS. New Guideline for the  
Reporting of Studies Developing, Validating, or Updating a Multivariable Clinical  
Prediction Model: The TRIPOD Statement. Advances in anatomic pathology.  
2015;22(5):303-5.
27. Kuehni CE, Brooke AM, Strippoli MP, Spycher BD, Davis A, Silverman M.  
Cohort profile: the Leicester respiratory cohorts. International journal of  
epidemiology. 2007;36(5):977-85.
28. Boyd A, Golding J, Macleod J, Lawlor DA, Fraser A, Henderson J, et al.  
Cohort Profile: the 'children of the 90s'--the index offspring of the Avon  
Longitudinal Study of Parents and Children. International journal of  
epidemiology. 2013;42(1):111-27.


29. Van Calster B, Nieboer D, Vergouwe Y, De Cock B, Pencina MJ, Steyerberg EW. A calibration hierarchy for risk models was defined: from utopia to empirical data. *Journal of clinical epidemiology*. 2016;74:167-76.
30. Collins GS, Ogundimu EO, Altman DG. Sample size considerations for the external validation of a multivariable prognostic model: a resampling study. *Statistics in medicine*. 2016;35(2):214-26.
31. Youden WJ. Index for rating diagnostic tests. *Cancer*. 1950;3(1):32-5.
32. Henderson J, Granell R, Heron J, Sherriff A, Simpson A, Woodcock A, et al. Associations of wheezing phenotypes in the first 6 years of life with atopy, lung function and airway responsiveness in mid-childhood. *Thorax*. 2008;63(11):974-80.
33. Spycher BD, Silverman M, Pescatore AM, Beardsmore CS, Kuehni CE. Comparison of phenotypes of childhood wheeze and cough in 2 independent cohorts. *The Journal of allergy and clinical immunology*. 2013;132(5):1058-67.
34. Lee SY, Kim HB, Yu J, Hong SJ. Exercise-induced asthma in children. *Expert review of clinical immunology*. 2009;5(2):193-207.
35. Peduzzi P, Concato J, Kemper E, Holford TR, Feinstein AR. A simulation study of the number of events per variable in logistic regression analysis. *Journal of clinical epidemiology*. 1996;49(12):1373-9.
36. van Smeden M, de Groot JA, Moons KG, Collins GS, Altman DG, Eijkemans MJ, et al. No rationale for 1 variable per 10 events criterion for binary logistic regression analysis. *BMC medical research methodology*. 2016;16(1):163.





\*Score based on items described in table 3 for ALSPAC and LRC, respectively. Abbreviations; ALSPAC: Avon Longitudinal Study of Parents and Children, LRC: Leicestershire Respiratory Cohorts, IQR: Interquartile range

	0	1	2	3	4	5	6	7	8	9	10	11	12	13
Sens	1.00	0.98	0.91	0.79	0.69	0.61	0.53	0.46	0.38	0.27	0.14	0.06	0.01	0.00
Spec	0.00	0.05	0.28	0.60	0.76	0.83	0.87	0.91	0.94	0.97	0.99	1.00	1.00	1.00
PPV	0.14	0.14	0.17	0.24	0.32	0.36	0.39	0.44	0.50	0.56	0.65	0.69	0.63	1.00
NPV	-	0.95	0.95	0.95	0.94	0.93	0.92	0.91	0.90	0.89	0.88	0.87	0.86	0.86
LR+	1.00	1.03	1.27	1.97	2.87	3.51	3.94	4.95	6.30	7.96	11.57	13.67	10.35	-
LR-	-	0.35	0.31	0.35	0.41	0.47	0.55	0.59	0.66	0.76	0.87	0.95	0.99	1.00







**Table 1:** Inclusion criteria and outcome definitions in LRC and ALSPAC

<b>LRC: items for inclusion criteria* (at age 1-3 years)</b>	<b>Answer categories</b>	<b>ALSPAC: items for inclusion criteria* (at age 0.5, 1.5, 2.5 years)</b>	<b>Answer categories</b>	<b>Comparability</b>
Has your child had wheezing or whistling in the chest in the last 12 months?	Yes, no	Has he had any of the following the last 12 months, wheezing?	Yes and saw a doctor Yes but did not see doctor No did not have	Good
Does your child usually have a cough without colds?	Yes, no	Has he had any of the following the last 12 months, cough?	Yes and saw a doctor Yes but did not see doctor No did not have	Moderate
In the last 12 months, has your child had a dry cough at night, apart from a cough associated with a cold or a chest infection?	Yes, no	No question	-	-
How often did your child see a GP for coughing or wheezing during the last 12 months?	Never, once, 2-3 times, 4-6 times, 7 or more times	Has he had any of the following the last 12 months, wheezing?	Yes and saw a doctor Yes but did not see doctor No did not have	Good
In the last 12 months, has wheezing or asthma resulted in your child: (4 categories: referred/admitted to hospital, attending/calling ER or GP)	Yes, no	No question	-	-
<b>LRC: items for outcome definition® (at 8 years)</b>	<b>Answer categories</b>	<b>ALSPAC: items for outcome definition® (at 7.5 years)</b>	<b>Answer categories</b>	<b>Comparability</b>
Has your child had wheezing or whistling in the chest in the last 12 months?	Yes, no	Has he had any of the following in the past 12 months, wheezing?	Yes and saw a doctor Yes but did not see doctor No did not have	Very good
Did your child take any of the following during the last 12 months? (4 categories: inhalers by content/type)	Yes, no, don't know	Please indicate which of the following have been given to your child the last 12 months. - Asthma medication?	Never Yes for 1-2 episodes only Yes for 3 or more episodes	Very good

**\*Inclusion criteria LRC:** Wheeze or cough (cough without colds or cough at night) with 1 or more visits to the doctor for wheeze or cough during the past 12 months). **Inclusion criteria ALSPAC:** Wheeze or cough during the past 12 months and saw a doctor for one of these problems (answer category: yes and saw a doctor). **®Outcome definition LRC:** 'Yes' to wheeze and use of asthma medication past 12 months. **Outcome definition ALSPAC:** 'Yes' to wheeze and use of asthma medication past 12 months.



**Table 2:** Comparison of study characteristics and demographic factors in development cohort (LRC) and external validation cohort (ALSPAC)

	<b>Development cohort (LRC) N=1226</b>	<b>Validation cohort (ALSPAC) N=2690</b>
<b>Location</b>	Leicestershire (United Kingdom)	Bristol (United Kingdom)
<b>Study design</b>	Prospective cohort (from birth)	Prospective cohort (from pregnancy)
<b>Recruitment</b>	General population random sample	General population random sample
<b>Year of birth</b>	1995-1997	1991-1992
<b>Sex</b>		
male	678 (55)	1433 (54)
<b>Ethnicity</b>		
White	797 (69)	2580 (98)
South Asian	305 (26)	-
Other	57 (5)	52 (2)
<b>Baseline Assessment</b>		
<b>Age*</b>		
1 year	336 (27)	763 (28)
2 years	702 (57)	1516 (56)
3 years	188 (15)	411 (15)
<b>Wheeze* prevalence</b>	766 (62)	791 (29)
<b>Cough* prevalence</b>	1085 (89)	2654 (99)
<b>Follow-up Assessment</b>		
<b>Age</b>		
6 years	336 (27)	
7 years	702 (57)	2690 (100)
8 years	188 (15)	
<b>Wheeze* prevalence</b>	427 (35)	451 (17)
<b>Cough* prevalence</b>		
<b>Use of asthma medication*</b>	345 (28)	586 (22)
<b>Wheeze* + use of asthma medication*</b>	345 (28)	373 (14)

This table is displayed using n (%) unless otherwise stated. \*The age distribution at baseline in ALSPAC was matched to the baseline age distribution in LRC, \* in the past 12 months. Prevalence of wheeze and cough is so high, because only children with lower respiratory symptoms were included.

**Table 3:** Questionnaire items used for scoring and their distribution in LRC and ALSPAC

Item Nr.	Question item in LRC	Score value	(%)	Questionnaire item in ALSPAC	Score value	(%)	Comparability
1	What is the child's sex	Female = 0	(45)	Sex	Female = 0	(47)	Perfect
		Male = 1	(55)		Male = 1	(53)	
2	How old is the child?	1 years = 0	(27)	Age	1 years = 0	(28)	Perfect
		2 years = 1	(57)		2 years = 1	(57)	
		3 years = 1	(15)		3 years = 1	(15)	
3	In the last 12 months, has the child had wheezing or whistling in the chest even without having a cold or flu?	No = 0	(82)	Since she was 6/18/30* months old has she had any periods when there was wheezing with whistling on her chest when she breathed?	No = 0	(71)	Moderate. Question does not include 'without cold'
		Yes = 1	(18)		Yes = 1	(29)	
4	How many attacks of wheeze has the child had during the last 12 months?	0-3 = 0	(77)	Has your baby ever had wheezing with whistling on her chest when she breathed?	0-3 = 0	(82)	Very good
		>3 = 2	(23)	b) How many separate times has this happened	>3 = 2	(18)	
5	In the last 12 months, how much did wheezing interfere with your child's daily activities?	Never=0	(64)	Proxy: 'how many days altogether would you say he had wheezed in the past 12 months?'	0-3 days = 0	(77)	Poor. Different question.
		A little = 1	(26)		4-19 days = 1	(16)	
		A lot = 2	(10)		20 or more days = 2	(7)	
6	Do these wheezing attacks cause him/her to be short of breath?	Never = 0	(65)	Since she was 6/18/30* months old has she had any periods when there was wheezing with whistling on her chest when she breathed?	No for all = 0	(84)	Very good
		Sometimes = 2	(29)	d) Was he breathless (struggling for breath) during any of these times?	Yes for some = 2	(15)	
		Always = 3	(6)	has your baby ever had wheezing with whistling on her chest when she breathed?	Yes for all = 3	(1)	
7	In the last 12 months, did exercise (playing, running) or laughing, crying or excitement cause wheezing or coughing in the child?	No = 0	(61)	g) what do you think brings them on? (exercise, emotion)	No = 0	(99)	Moderate. Optional free text field – few answers
		Yes = 1	(39)		Yes = 1	(1)	
8	In the last 12 months, did contact with dust, grass, pets or other animals cause wheezing or coughing in the child?	No = 0	(93)	g) what do you think brings them on? (allergy)	No = 0	(99)	Moderate. Optional free text field – few answers
		Yes = 1	(7)		Yes = 1	(1)	
9	Has the child ever had eczema?	No = 0	(57)	Has the baby had a rash in the joints and creases of her body (e.g. behind the knees, under the arms)?	No = 0	(71)	Good. Asking about rash instead of eczema
		Yes = 1	(43)		Yes = 1	(29)	
10	Has the child's parents ever suffered from wheezing, asthma or bronchitis?	None = 0	(52)	Have you ever had any of the following problems: asthma/ Wheezing past 2 years	None = 0	(65)	Moderate. Information asked from partner instead of father.
		Mother = 1	(17)	Have you had wheeze or bronchitis since the child was born (8 month after birth)	Mother or father = 1	(31)	
		Father = 1	(22)		Both = 1	(4)	
		Both = 1	(9)				

\*ages correspond to age 12 months prior to questionnaire mailing

Table 4: Predictive performance of PARC for main analysis and sensitivity analyses in ALSPAC and LRC (definitions of main and sensitivity analyses in table E1)

	ALSPAC	n	Cases (%)	Sens	Spec	PPV	NPV	LR+	LR-	AUC	R <sup>2</sup>	Brier score
<b>A1</b>	<b>Main analysis</b>	2690	373 (14)	0.69	0.76	0.32	0.94	2.87	0.41	0.77	0.23	0.13
<b>A2</b>	<b>Altered inclusion criteria</b>											
A2.1	Only children aged 1 year	3583	439 (12)	0.51	0.80	0.26	0.92	2.53	0.61	0.71	0.13	0.06
A2.2	Only children aged 2 years	2817	410 (14)	0.69	0.72	0.29	0.93	2.42	0.44	0.76	0.21	0.07
A2.3	Only children aged 3 years	2238	396 (19)	0.62	0.82	0.43	0.91	3.46	0.46	0.78	0.26	0.21
A2.4	Wheeze past 12 months	1423	326 (23)	0.81	0.46	0.31	0.89	1.49	0.42	0.73	0.18	0.08
A2.5	Cough past 12 months	6351	554 (9)	0.52	0.87	0.28	0.95	4.11	0.55	0.76	0.20	0.07
<b>A3</b>	<b>Altered scoring variables</b>											
A3.1	Exclude trigger variables	2690	373 (14)	0.69	0.76	0.32	0.94	2.89	0.41	0.77	0.23	0.13
<b>A4</b>	<b>Altered outcome definition</b>											
A4.1	Severity: Wheeze past 12 months and use of asthma medication at 3 or more episodes	2688	307 (11)	0.70	0.75	0.26	0.95	2.78	0.40	0.78	0.23	0.06
<b>LRC</b>												
<b>L1</b>	<b>Main analysis</b>	1226	345 (28)	0.79	0.57	0.42	0.87	1.83	0.38	0.78	0.28	0.22
<b>L2</b>	<b>Altered inclusion criteria</b>											
L2.1	Wheeze past 12 months	1033	330 (32)	0.72	0.53	0.42	0.80	1.52	0.53	0.69	0.17	0.14
<b>L3</b>	<b>Altered scoring variables</b>											
L3.1	Exclude trigger variables	1226	345 (28)	0.74	0.63	0.44	0.86	2.04	0.40	0.77	0.28	0.22
L3.2	Exchange wheeze without colds with current wheeze	1226	345 (28)	0.82	0.53	0.40	0.88	1.73	0.34	0.77	0.28	0.21
<b>L4</b>	<b>Altered outcome definition</b>											
L4.1	Severity: Wheeze past 12 months more than 4 episodes and use of asthma medication	1030	86 (8)	0.86	0.61	0.17	0.98	2.19	0.23	0.84	0.32	-0.15*

Sens, Spec, PPV, NPV, LR+, LR- are all presented for PARC score = 4. Abbreviations; R<sup>2</sup>: Nagelkerke's, Sens: sensitivity, Spec: Specificity, PPV: positive predictive value, NPV: negative predictive value, LR-: Negative likelihood ratio, LR+: positive likelihood ratio. \*The negative scaled Brier score is due to the large difference in the prevalence of the outcome in main analysis and the corresponding sensitivity analysis.

## Supplemental Text E3:

### Definition of the scaled Brier score and Nagelkerke's R<sup>2</sup>

In the following, let  $y_i$  represent the outcome for child  $i$  taking on the value 1 if the child has later asthma and 0 otherwise, and  $p_i$  the predicted probability based on the baseline information of that child using the PARC tool. Let  $n$  be the total number of children in the cohort and  $\bar{y} = \frac{1}{n} \sum_{i=1}^n y_i$  be the prevalence of the outcome.

#### Scaled Brier score

The Brier score evaluates the mean squared error of prediction<sup>1</sup>:

$$Brier = \frac{1}{n} \sum_{i=1}^n (p_i - y_i)^2$$

This score takes on the minimum value of 0 when  $p_i$  predicts  $y_i$  perfectly. To obtain a similar interpretation for this statistic as for R<sup>2</sup> in linear regression models, we rescale this score as

$$Brier_{scaled} = 1 - \frac{Brier}{Brier_{max}}$$

where  $Brier_{max}$  is the Brier score evaluated with  $\bar{y}$  replacing  $p_i$  in the formula above.  $Brier_{scaled}$  takes on values between 0 and 1 with 1 representing perfect prediction and 0 a non-informative prediction model in which the outcome for each child is predicted with a constant equal to the prevalence  $\bar{y}$ .

#### Nagelkerke's R<sup>2</sup>

Nagelkerke's R<sup>2</sup> compares the likelihood of the prediction model with that of a non-informative model in which the outcome for each child is predicted with a constant equal to the prevalence  $\bar{y}$ . It is calculated as follows<sup>1, 2</sup>:

$$R_{NK}^2 = \frac{1 - (L_0/L_1)^{2/n}}{1 - (L_0)^{2/n}}$$

Where  $L_1$  and  $L_0$  are the likelihood of PARC and the non-informative models respectively. The denominator of this equation is simply used for rescaling and represents the maximum value that the numerator can attain (in a perfect model  $L_1 = 1$ ). As  $Brier_{scaled}$ , the statistic  $R_{NK}^2$  thus takes on values between 0 and 1 with 1 representing perfect prediction and 0 the non-informative model. The likelihood function evaluated for the predictions of the PARC tool is given by:

$$L_1 = \prod_{i=1}^n p_i^{y_i} (1 - p_i)^{(1-y_i)}$$

$L_0$  is calculated by replacing  $p_i$  with  $\bar{y}$  in this formula.

## References

1. Steyerberg EW. Clinical Prediction Models: A Practical Approach to Development, Validation, and Updating. Berlin: Springer-Verlag; 2009.
2. Smith TJ, McKenna CM. A Comparison of Logistic Regression Pseudo R<sup>2</sup> Indices. Multiple Linear Regression Viewpoints 2013; 39:17-26.

Table E2 (supplementary): Overview of the definitions of main analysis and sensitivity analyses in ALSPAC and LRC.

Analysis		Definition changed	Definition
ALSPAC			
<b>A1</b>	<b>Main Analysis</b>	-	<b>Inclusion criteria:</b> Wheeze or Cough in the past 12 months and saw a doctor for this. <b>Scoring variables:</b> 1)Sex 2)age 3)wheeze past 12 months 4)number of wheeze attacks 5)number of days wheezed 6)breathless due to wheeze 7)exercise as trigger for wheeze 8)allergy as trigger for wheeze 9)rash in the joints 10)family history of asthma or bronchitis. <b>Outcome definition:</b> Wheeze past 12 months and use of asthma medication.
<b>A2</b>	<b>Altered inclusion criteria</b>		
A2.1	Only children aged 1 year	Inclusion criteria	Age excluded as prediction variable
A2.2	Only children aged 2 years	Inclusion criteria	Age excluded as prediction variable
A2.3	Only children aged 3 years	Inclusion criteria	Age excluded as prediction variable
A2.4	Wheeze past 12 months	Inclusion criteria	Past 12 months: <i>Has he/she had periods when there was wheezing with whistling on his/her chest? or Has he/she had wheeze?</i>
A2.5	Cough past 12 months	Inclusion criteria	Past 12 months: <i>Has he/she ever had a time when he has coughed on and off for at least 2 days? or Has he/she had cough?</i>
<b>A3</b>	<b>Altered scoring variables</b>		
A3.1	Exclude trigger variables	Scoring variables	Exclude item 7 and 8: Exercise and allergy as triggers for wheeze
<b>A4</b>	<b>Altered outcome definition</b>		
A4.1	Severity: Wheeze past 12 months and use of asthma medication at 3 or more episodes	Outcome	<i>Has he had wheeze in the past 12 months? AND Please indicate which of the following have been given to your child in the past 12 months (answer category: asthma medication, on 3 or more episodes)</i>
LRC			
<b>L1</b>	<b>Main analysis</b>	-	<b>Inclusion criteria:</b> Wheeze or cough apart from colds in the past 12 months and saw a doctor for wheeze or cough. <b>Scoring variables:</b> 1)Sex 2)age 3)wheeze apart from colds 4)number of wheeze attacks 5)wheeze interference with daily life 6)shortness of breath due to wheeze 7)exercise or emotion as trigger for wheeze 8)allergy as trigger for wheeze 9)child ever had eczema 10)family history of wheeze, asthma or bronchitis. <b>Outcome:</b> wheezing or whistling in the chest in the last 12 months AND use of asthma medication
<b>L2</b>	<b>Altered inclusion criteria</b>		
L2.1	Wheeze past 12 months	Inclusion criteria	<i>Has your child has wheezing or whistling in the chest in the last 12 months?</i>
<b>L3</b>	<b>Altered scoring variables</b>		
L3.1	Exclude trigger variables	Scoring variables	Exclude item 7 and 8: Exercise and allergy as triggers for wheeze
L3.2	Exchange wheeze without colds with current wheeze	Scoring variables	Exchange item 3 'wheeze without colds' with 'wheezing or whistling in the chest in the last 12 months'
<b>L4</b>	<b>Altered outcome</b>		
L4.1	Severity: Wheeze past 12 months more than 4 episodes and use of asthma medication	Outcome	More than 4 episodes of wheeze past 12 months and use of asthma medication past 12 months

Supplementary table E3: Comparison of four asthma prediction tools for preschool children

	PARC	API*	Isle of Wight	PIAMA
No. (included in analysis)	1226	776	336	2054
Inclusion criteria				
Age (y)	1-3	2-3	4	1-4
Symptoms	Health care visit because of respiratory problems plus $\geq 1$ of the following: wheeze, cough without colds, cough at night	Entire cohort (including a majority of children without symptoms)	Wheeze at ages 1,2 and 4 y	Wheeze or cough at night without colds in the past 12 months
Outcome definition				
Age (y)	6-8	8	10	7-8
Prediction interval (y)	5	5	6	3-7
Criteria	Wheeze plus asthma medication (past 12 months)	Doctor's diagnosis of asthma plus current wheeze or $>3$ episodes of wheeze (past 3 months)	Current wheeze	At ages 7 and 8 y: current wheeze or prescription of inhaled corticosteroids or doctor's diagnosis of asthma (past 12 months)
Outcome prevalence	28%	14%	37%	12%
Predictor variables included in tool	Male sex, age, wheeze without colds, frequent wheeze, activity disturbance, shortness of breath, exercise-related wheeze/cough, aeroallergen-related wheeze/cough, eczema, parental asthma or bronchitis	Wheeze, frequent wheeze, wheeze without colds, eczema, parental asthma, blood eosinophilia, allergic rhinitis	Family history of asthma, recurrent chest infections (at 2 y), skin prick test positive (at 4 y), nasal symptoms (at 1 y)	Male sex, post term delivery, wheeze/dyspnea without colds, frequent wheeze, eczema, respiratory infections, inhalation medication (parents), parental education
Method used to derive tool	Penalized logistic regression	Combination of predictors was chosen that yielded the highest PPV and specificity	Stepwise backward logistic regression	Stepwise backward logistic regression
Performance measures	Score cutoff $\geq 5$	Loose API	Score cutoff $\geq 3$	Score cutoff $\geq 20$
Youden index	0.43	0.32	0.38	0.36
Sensitivity (%)	72	51	53	60
Specificity (%)	71	81	85	76
PPV (%)	49	29	68	23
NPV (%)	86	91	74	94
+LR	2.48	7.43	3.41	2.50
-LR	0.39	0.75	0.56	0.53

PARC: Predicting Asthma Risk in Children (19), API: Asthma Predictive Index (10), Isle of Wight risk score (13), PIAMA risk score (18), Youden Index: Reported for cutoff where the sum of sensitivity and specificity was maximal. It is possible that a higher sum of sensitivity and specificity exists at a cutoff point that was not reported in the respective studies. PPV: positive predictive value, NPV: negative predictive value, +LR: positive likelihood ratio, -LR: negative likelihood ratio

\*To have a prediction interval comparable with the one in our tool, we focused here on the API for prediction at 8 years.